Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Research Report 2024
Phosphodiesterase type 5 inhibitor (PDE5 inhibitor) is a drug used to block degradation of cgmp-specific phosphodiesterase type 5 (PDE5) loop GMP in smooth muscle cell lining supplying blood vessels to various tissues.These drugs dilate the cavernous penis, promote erections with sexual stimulation, and are used to treat erectile dysfunction (ED).Sildenafil is the first effective oral therapy for ED.Because PDE5 is also present in the wall of the smooth muscle arterioles of the inner lung, sildenafil and tadalafil dilate these vessels and are FDA approved for the treatment of pulmonary hypertension.
According to Mr Accuracy reports’s new survey, global Phosphodiesterase Type 5 (PDE5) Inhibitor market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Phosphodiesterase Type 5 (PDE5) Inhibitor market research.
Key companies engaged in the Phosphodiesterase Type 5 (PDE5) Inhibitor industry include Eli Lilly, Pfizer, Bayer, Novartis AG, Merck, GlaxoSmithKline plc, Roche, AstraZeneca and BaiYunShan General Factory, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Phosphodiesterase Type 5 (PDE5) Inhibitor were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Phosphodiesterase Type 5 (PDE5) Inhibitor market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Phosphodiesterase Type 5 (PDE5) Inhibitor market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Eli Lilly
Pfizer
Bayer
Novartis AG
Merck
GlaxoSmithKline plc
Roche
AstraZeneca
BaiYunShan General Factory
SK Chemicals
Teva Pharma
Dong-A ST
Metuchen Pharma
Seoul Pharma
Vectura Group
Segment by Type
Sildenafil
Tadalafil
Avanafil
Vardenafil
Hospital
Retail Pharmacy
Online Pharmacies
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Phosphodiesterase Type 5 (PDE5) Inhibitor report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Phosphodiesterase Type 5 (PDE5) Inhibitor market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Phosphodiesterase Type 5 (PDE5) Inhibitor market research.
Key companies engaged in the Phosphodiesterase Type 5 (PDE5) Inhibitor industry include Eli Lilly, Pfizer, Bayer, Novartis AG, Merck, GlaxoSmithKline plc, Roche, AstraZeneca and BaiYunShan General Factory, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Phosphodiesterase Type 5 (PDE5) Inhibitor were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Phosphodiesterase Type 5 (PDE5) Inhibitor market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Phosphodiesterase Type 5 (PDE5) Inhibitor market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Eli Lilly
Pfizer
Bayer
Novartis AG
Merck
GlaxoSmithKline plc
Roche
AstraZeneca
BaiYunShan General Factory
SK Chemicals
Teva Pharma
Dong-A ST
Metuchen Pharma
Seoul Pharma
Vectura Group
Segment by Type
Sildenafil
Tadalafil
Avanafil
Vardenafil
Segment by Application
Hospital
Retail Pharmacy
Online Pharmacies
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Phosphodiesterase Type 5 (PDE5) Inhibitor report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices